Dan Skovronsky
Dr. Dan Skovronsky is the Chief Scientific Officer at Eli Lilly, where he has played a pivotal role in the development of innovative treatments for diabetes and obesity. Recently, he announced promising results from clinical trials of orforglipron, an experimental GLP-1 pill that significantly helped participants with type 2 diabetes lose weight and lower blood sugar levels.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 8.00 | 0.02% | +0% | 331,002,651 | 72,748 | $21,000,000 | 4,615$ |
| Totals | 1 | 331,002,651 | 72,748 | $21,000,000 | 4,615$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Dr. Dan Skovronsky, Lilly’s chief scientific officer, expressed confidence in the trial results before they were released.
8